Last reviewed · How we verify
Biological: Solrikitug high dose
Solrikitug is a high-dose biologic that targets the IL-1β pathway.
Solrikitug is a high-dose biologic that targets the IL-1β pathway. Used for Treatment of Still's disease.
At a glance
| Generic name | Biological: Solrikitug high dose |
|---|---|
| Sponsor | Uniquity One (UNI) |
| Drug class | IL-1β inhibitor |
| Target | IL-1β |
| Modality | Biologic |
| Therapeutic area | Inflammation |
| Phase | Phase 2 |
Mechanism of action
Solrikitug works by binding to the IL-1β protein, thereby inhibiting its activity and reducing inflammation. This mechanism is thought to be beneficial in treating various inflammatory conditions.
Approved indications
- Treatment of Still's disease
Common side effects
- Injection site reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological: Solrikitug high dose CI brief — competitive landscape report
- Biological: Solrikitug high dose updates RSS · CI watch RSS
- Uniquity One (UNI) portfolio CI